Are blood thinners post-op killers?April 01, 2008New study shows that the use of powerful anticoagulants to prevent pulmonary embolism may actually lead to more deaths after surgery Current US guidelines for the prescription of potent anticoagulants by surgeons who perform joint replacement operations could be doing patients more harm than good, according to Dr. Nigel Sharrock and his team from the Hospital for Special Surgery in New York. They argue for a revision of the American College of Chest Physicians' guidelines, in light of their review showing that the use of powerful anticoagulants to prevent pulmonary embolism may actually lead to more deaths among patients who take these drugs. The paper1 was published in the March issue of Springer's journal Clinical Orthopaedics and Related Research. Anticoagulants are routinely prescribed before and after total hip and knee replacement operations to reduce the risk of thrombosis, and death from pulmonary embolism in particular, as recommended by the Chest Physicians Consensus Statement. During the last decades, deaths from pulmonary embolism have fallen significantly due to a combination of advancements in anesthesia, better surgical techniques and care pre- and post-surgery, as well as a better understanding of how thrombosis develops as a result of surgery. In light of these developments, Sharrock and his team looked at whether the prescription of potent anticoagulants by surgeons who perform joint replacement operations is still warranted, as these drugs also have side effects.
The authors reviewed 20 studies among a total of just over 28,000 patients undergoing joint replacement surgery who were prescribed medication to reduce the risk of thrombosis. They compared the total number of deaths and cases of non-fatal pulmonary embolism between three frequently used prevention protocols worldwide. Patients in group A received potent anticoagulants such as low molecular weight heparin; those in group B received local spinal or epidural anesthesia, pneumatic compression and aspirin; patients in group C were prescribed slow-acting oral anticoagulants such as warfarin. The lowest number of deaths occurred in patients in group B. Patients in groups A and C were more than twice as likely to have died as those in group B. There was no difference in the number of deaths between groups A and C. Patients in group A were also at 60-70% greater risk of non-fatal pulmonary embolism than those in group B, indicating that pulmonary embolism occurs despite the use of powerful anticoagulants. Sharrock and colleagues conclude that "the American College of Chest Physicians should reconsider their guidelines to reflect the fact that pulmonary embolism occurs despite the use of potent anticoagulants and may, in fact, expose patients to increased mortality after surgery." In their view, the current recommendations often result in physicians feeling compelled to prescribe these anticoagulants to avoid potential litigation when, in reality, these drugs could be doing more harm than good. Reference 1. Sharrock NE et al (2008). Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res; 466:714-721 (DOI 10.1007/s11999-007-0092-4). Springer Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Conservation Beta-catenin Biofilms Particle Accelerator Wildlife Conservation Miscarriage Mortality Neural Stem Cells Parkinsons disease DNA damage Polycystic kidney disease Television Collagen Metastasis Cancer Diagnosis Flavonoids Alcoholics Nuclear Power Imaging technique Sharks Mosquitoes General Relativity Polio ALS Spiders
See More: Science News Tags | |||||||||||||||||||||
|
Related Anticoagulant Current Events and Anticoagulant News Articles New tool calculates risk of bleeding in heart attack patients With eight basic medical facts in hand, doctors can now estimate the risk of bleeding for a patient having a heart attack. For old or young dialysis patients, AV fistulas remain pure gold A new study shows that for those individuals with chronic kidney disease, it doesn't matter if you're young or old: arteriovenous (AV) fistulas remain the gold standard for maintaining access to one's circulatory system to provide life-sustaining dialysis. Mutant rats resist warfarin A new series of mutations have been discovered that allow rats to resist the effects of the popular poison warfarin. Research published in the open access journal BMC Genetics describes eighteen new genetic changes found in rats from four continents. Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis? Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate. Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis? Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate. Research highlights new approaches to prevent blood clots Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. A reversal of thinking: How women with lupus can increase chance for healthy pregnancies In the not so distant past, women with systemic lupus erythematosus (SLE), an autoimmune disease, were advised not to have children, and if they became pregnant, to have therapeutic abortions to prevent severe flares of their lupus. DNA research taking guesswork out of finding the 'therapeutic window' It's only spit, but what's inside your saliva may help solve a dosing dilemma facing doctors and patients. HORIZONS AMI will help set guidelines for drug and stent therapy The HORIZONS AMI clinical trial measuring the safety and efficacy of the use of the medication bivalirudin compared to standard drug therapy - heparin and glycoprotein IIb/IIIa inhibitors -- in heart attack patients who receive angioplasty, found that after 1 year, use of bivalirudin resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding. Women may stop anticoagulants after blood clots Women may safely discontinue oral anticoagulants (blood thinners) after 6 months of treatment following a first unprovoked venous blood clot (thromboembolism) if they have no or one risk factor. More Anticoagulant Current Events and Anticoagulant News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||